CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-05 | FARRELL PETER C Director | Sale 10b5-1 | −8,000 | $225.00 | $1.8M | 52,773 |
| 2026-07-07 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-07-07 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $218.55 | $1.1M | 466,223 |
| 2026-07-07 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 19,966 | ||
| 2026-06-08 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-06-08 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $193.96 | $968K | 466,256 |
| 2026-06-08 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 24,957 | ||
| 2026-06-01 | Rider Michael J Global General Counsel | Shares withheld for taxes | −268.74 | $190.57 | $51K | 9,488 |
| 2026-05-07 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-05-07 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $207.82 | $1.0M | 466,223 |
| 2026-05-07 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 29,948 | ||
| 2026-04-07 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-04-07 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $225.50 | $1.1M | 466,223 |
| 2026-04-07 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 34,939 | ||
| 2026-04-01 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $224.31 | $224K | 83,495 |
| 2026-04-01 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $225.00 | $450K | 60,773 |
| 2026-03-09 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-03-09 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $251.03 | $1.3M | 466,223 |
| 2026-03-09 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 39,930 | ||
| 2026-03-04 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $260.22 | $520K | 62,773 |
Page 2 of 18 · 355 trades